DRESS syndrome primary prevention

Revision as of 19:28, 21 September 2015 by YazanDaaboul (talk | contribs)
Jump to navigation Jump to search

DRESS syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating DRESS syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

DRESS syndrome On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of DRESS syndrome

All Images
syndrome X-ray X-rays
syndrome Ultrasound Echo & Ultrasound
syndrome CT CT Images
syndrome MRI MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on DRESS syndrome

CDC on DRESS syndrome

DRESS syndrome in the news

Blogs on DRESS syndrome

Directions to Hospitals Treating DRESS syndrome

Risk calculators and risk factors for DRESS syndrome

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Yazan Daaboul, M.D.; Serge Korjian M.D.

Overview

There are no established measures for the primary prevention of DRESS syndrome. Primary prevention measures may include slow dose escalation of drugs (e.g. anticonvulsants), genetic counseling, and in vitro impaired detoxification testing.

Primary Prevention

There are no established measures for the primary prevention of DRESS syndrome. Primary prevention measures may include the following:

  • Slow dose escalation of agents known to be associated with DRESS syndrome[1]
  • Genetic counseling to relatives of patients with DRESS syndrome[2]
  • In vitro impaired detoxification testing using lymphocyte toxicity assays among individuals with affected first-degree relatives[2]

References

  1. Fitton A, Goa KL (1995). "Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy". Drugs. 50 (4): 691–713. PMID 8536554.
  2. 2.0 2.1 Sullivan JR, Shear NH (2000). "What are some of the lessons learnt from in vitro studies of severe unpredictable drug reactions?". Br J Dermatol. 142 (2): 205–7. PMID 10730749.